Article

Randomized, Double-Blind Trial of Olanzapine Versus Placebo in Patients Prodromally Symptomatic for Psychosis

Department of Psychiatry, University of Toronto, Toronto, Ontario, Canada
American Journal of Psychiatry (Impact Factor: 13.56). 06/2006; 163(5):790-9. DOI: 10.1176/appi.ajp.163.5.790
Source: PubMed

ABSTRACT This study assessed the efficacy of olanzapine in delaying or preventing conversion to psychosis and reducing symptoms in people with prodromal symptoms of schizophrenia.
This randomized trial occurred at four North American clinics in the Prevention Through Risk Identification, Management, and Education project. Outpatients received olanzapine (5-15 mg/day, N=31) or placebo (N=29) during a 1-year double-blind treatment period and no treatment during a 1-year follow-up period. Efficacy measures included the conversion-to-psychosis rate and Scale of Prodromal Symptoms scores.
During the treatment year, 16.1% of olanzapine patients and 37.9% of placebo patients experienced a conversion to psychosis, a nearly significant difference. The hazard of conversion among placebo patients was about 2.5 times that among olanzapine-treated patients, which also approached significance. In the follow-up year, the conversion rate did not differ significantly between groups. During treatment, the mean score for prodromal positive symptoms improved more in the olanzapine group than in the placebo group, and the mixed-model repeated-measures least-squares mean score showed significantly greater improvement between weeks 8 and 28 with olanzapine. The olanzapine patients gained significantly more weight (mean=8.79 kg, SD=9.05, versus mean=0.30 kg, SD=4.24).
A significant treatment difference in the conversion-to-psychosis rate was not demonstrated. However, these results may be influenced by low power. The nearly significant differences suggest that olanzapine might reduce the conversion rate and delay onset of psychosis. Olanzapine was efficacious for positive prodromal symptoms but induced weight gain. Further treatment research in this phase of illness is warranted.

Download full-text

Full-text

Available from: A. Preda, Jul 28, 2015
0 Followers
 · 
167 Views
  • Source
    • "For those at the highest end of the risk spectrum, early commencement of preventive treatments may win time in combatting the pathophysiological processes associated with psychosis onset (de Koning et al. 2009; Pasternak et al. 2012). In contrast, for those in the low-risk group, reliable risk estimation will prevent the potentially stigmatizing consequences of a psychiatric diagnosis and exposure to potentially harmful effects of pharmacological and other interventions (McGlashan et al. 2006). Clinical assessments alone for determination of transition risk to psychosis are problematic due to the fluctuating course of symptoms in high-risk individuals (Ruhrmann et al. 2010a). "
    [Show abstract] [Hide abstract]
    ABSTRACT: The concept of indicated prevention has proliferated in psychiatry, and accumulating evidence suggests that it may indeed be possible to prevent or delay the onset of a first episode of psychosis though adequate interventions in individuals deemed at clinical high risk (CHR) for such an event. One challenge undermining these efforts is the relatively poor predictive accuracy of clinical assessments used in practice for CHR individuals, often leading to diagnostic and therapeutic uncertainty reflected in clinical guidelines promoting a 'watch and wait' approach to CHR patients. Using data from published studies, and employing predictive models based on the odds-ratio form of Bayes' rule, we simulated scenarios where clinical interview, neurocognitive testing, structural magnetic resonance imaging and electrophysiology are part of the initial assessment process of a CHR individual (extended diagnostic approach). Our findings indicate that for most at-risk patients, at least three of these assessments are necessary to arrive at a clinically meaningful differentiation into high- intermediate-, and low-risk groups. In particular, patients with equivocal results in the initial assessments require additional diagnostic testing to produce an accurate risk profile forming part of the comprehensive initial assessment. The findings may inform future research into reliable identification and personalized therapeutic targeting of CHR patients, to prevent transition to full-blown psychosis.
    Journal of Neural Transmission 10/2014; DOI:10.1007/s00702-014-1325-9 · 2.87 Impact Factor
  • Source
    • "Unlike other trials, this study also reported a significant improvement in negative symptoms. However, a randomised, double-blind, placebo-controlled study of olanzapine reported no beneficial effects on functioning over placebo, despite significant improvement in positive symptoms (Woods et al., 2003; McGlashan et al., 2006). "
    [Show abstract] [Hide abstract]
    ABSTRACT: Transition to psychotic disorder has been the traditional outcome of interest for research in the at-risk mental state (ARMS). However, there is growing recognition that individuals with ARMS may function poorly regardless of whether they develop psychosis. We aimed to review the literature to determine whether there are specific factors associated with, or predictive of, functional impairment in the ARMS population.
    Schizophrenia Research 09/2014; 159(2-3). DOI:10.1016/j.schres.2014.09.012 · 4.43 Impact Factor
  • Source
    • "Early detection and treatment appears in the long term (15 years) to augment functioning, to increase recovery rates and to reduce the remaining deficits (ten Velden Hegelstad et al., 2012). However current antipsychotic drugs have not convincingly been shown to reduce conversion rates (McGlashan et al., 2006). The urgent need for novel antidepressants and antipsychotics is widely recognised (e.g. "
    [Show abstract] [Hide abstract]
    ABSTRACT: There is recognition that biomedical research into the causes of mental disorders and their treatment needs to adopt new approaches to research. Novel biomedical techniques have advanced our understanding of how the brain develops and is shaped by behaviour and environment. This has led to the advent of stratified medicine, which translates advances in basic research by targeting aetiological mechanisms underlying mental disorder. The resulting increase in diagnostic precision and targeted treatments may provide a window of opportunity to address the large public health burden, and individual suffering associated with mental disorders. While mental health and mental disorders have significant representation in the "health, demographic change and wellbeing" challenge identified in Horizon 2020, the framework programme for research and innovation of the European Commission (2014-2020), and in national funding agencies, clear advice on a potential strategy for mental health research investment is needed. The development of such a strategy is supported by the EC-funded "Roadmap for Mental Health Research" (ROAMER) which will provide recommendations for a European mental health research strategy integrating the areas of biomedicine, psychology, public health well being, research integration and structuring, and stakeholder participation. Leading experts on biomedical research on mental disorders have provided an assessment of the state of the art in core psychopathological domains, including arousal and stress regulation, affect, cognition social processes, comorbidity and pharmacotherapy. They have identified major advances and promising methods and pointed out gaps to be addressed in order to achieve the promise of a stratified medicine for mental disorders.
    European neuropsychopharmacology: the journal of the European College of Neuropsychopharmacology 10/2013; DOI:10.1016/j.euroneuro.2013.09.010 · 5.40 Impact Factor
Show more